Aim:To evaluate the presence of hemoglobinopathies in patients of microcytic hypochromic anemia. Material and Methods: This research included all patients who had microcytic hypochromic anemia and underwent HPLC owing to suspicion of having a hemoglobinopathy. The research eliminated those patients who had received blood transfusions during the last three months.There was a total of 956 individuals diagnosed with microcytic hypochromic anemia. Among them, 200 patients underwent HPLC and were included in the research group. Results: A total of 956 individuals were diagnosed with microcytic hypochromic anemia, of whom 200 were believed to have hemoglobinopathy and underwent HPLC testing. Out of a total of 124 instances, 62% were found to have an aberrant hemoglobin pattern, while the remaining cases showed a normal hemoglobin pattern. The results indicate that 30% of individuals are heterozygous for ᵝ Thalassemia, 2% are homozygous for ᵝ Thalassemia, 19.5% are heterozygous for HbS, 5.5% are homozygous for HbS, 2% are double heterozygous for HbS and ᵝ Thalassemia, 1% are heterozygous for HbE, 0.5% are homozygous for HbE, 0.5% are double heterozygous for HbE and ᵝ Thalassemia, 0.5% have HbJ Meerut, 0.5% are double heterozygous for HbS and HbE, and 38% have no genetic conditions (Normal).A typical chromatogram of a healthy adult typically displays mostly HbA0 (mean 84.21±3.75%), a modest proportion of HbA2 (mean 5.05±0.43%), and minimal amounts of HbF (mean 1.33±0.14%). The P2 and P3 windows were in a typical state.Conclusion: This area has a high occurrence of hemoglobinopathies, which suggests that giving iron supplements to all instances of microcytic hypochromic anemia without discrimination is pointless. Instead, there is a need for mass screening programs and genetic counseling.This work reaffirms that HPLC is a very effective and robust diagnostic method for directly identifying Hb variations.